[1] 中华医学会心血管病学分会,中国老年学学会心血管病专业委员会.华法林抗凝治疗的中国专家共识[J]. 中华内科杂志,2013,52(1):76-82. [2] Holbrook A, Schulman S, Witt D M, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J]. Chest, 2012,141(2 Suppl): e152S-184S. [3] 胡大一,张鹤萍,孙艺红,等. 华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J]. 中华心血管病杂志,2006,34(4): 295-298. [4] 中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会,中国生物医学工程学心律分会,等.心房颤动抗凝治疗中国专家共识[J]. 中华内科杂志,2012, 51(11):916-921. [5] 葛卫红.华法林抗凝治疗临床药师指导手册[M]. 北京: 人民卫生出版社, 2009:15. [6] Olesen J B, Lip G Y, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a‘real world’nationwide cohort study [J]. Thromb Haemost, 2011, 106(4): 739-749. [7] Beinema M J, Van D M, Brouwers J R, et al. Safety and efficacy outcomes of home and hospital warfarin Mmanagement within a pediatric anticoagulation clinic [J]. Journal of thrombosis and haemostasis, 2016, 14(3): 479-484. [8] 郭梦园,赵志刚,孙树森,等.新型口服抗凝药与华法林临床应用的比较[J].药品评价,2015,12(4):24-29. [9] Clarkesmith D E, Pattison H M, Lip G Y, et al. Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial[J]. PLoS One, 2013, 8( 9):e74037-74047. [10] Luger Sebastian, Hohmann Carina, Niemann Daniela, et al. Adherence to oral anticoagulant therapy in secondary stroke prevention-impact of the novel oral anticoagulants [J]. Patient Prefer Adherence,2015,9(1):1695-1705. |